Delivery of Chemically Stabilized RNAi molecules to the Central Nervous System
Time: 11am - 12pm ESTDate: December 1, 2022 Description: Dr. Godinho will talk about the developments on delivery and PK/PD of novel oligonucleotides for CNS applications Speaker: Bruno M.D.C. Godinho Sr. Scientist Atalanta Therapeutics ...
An insider’s view into the preclinical development of an approved exon skipping drug
Time: 11am - 12pm EST Date: November 3, 2022 Description: Dr. Arechavala works on developing new drugs for neuromuscular disorders. As there are not many for these rare diseases, neuromuscular disorders have been at the forefront of the clinical development of RNA based ...
Site-specific detection of mutagenic DNA damage with an artificial nucleotide
Time: 11am - 12pm EST Date: October 27, 2022 Description: Incorporating nucleotides with altered structures that are derived synthetically is a strategy that has been used widely to interrogate biological processes involving DNA. Particularly, synthetic nucleotides able to stabilize damaged over undamaged templates ...
OTS President’s Pick Paper – October 2022
I would like to thank everyone who attended OTS 2022, whether in person or virtual. Special thanks to Keith Gagnon and Annemieke Aartsma-Rus and the entire organizing group for putting together such a great schedule of talks. Masad Damha coordinated the intricate network of award ...
Interview with Saul Martinez Montero, PhD
Saul Martinez Montero, PhD, Executive Director, Head of Chemistry BaseCure Therapeutics How did you become interested in the field of oligonucleotides? My graduate studies focused on nucleoside synthesis and on the applications of nucleosides as antiviral agents. In 2012, towards the end of my PhD, ...
Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR
People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according to patients who received it in the clinical trial. ATTRv is a progressive, debilitating, ...
2022 Paper of the Year Award – Basic Research Category
Tetsuya Nagata, Takanori Yokota, et al, Nature Biotechnology (2021). https://doi.org/10.1038/s41587-021-00972-x Takanori Yokota, MD, PhD Tokyo Medical and Dental University Biography: Dr. Yokota graduated from Tokyo Medical and Dental University in 1984 and completed his Residency and Fellowship in Musashino Red Cross Hospital ...
2022 Paper of the Year Award – Basic Research Category
Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates Kirk M. Brown, Martin A. Maier, Vasant Jadhav, et al, Nature Biotechnology (2022). https://doi.org/10.1038/s41587-022-01334-x Vasant Jadhav, PhD Alnylam Pharmaceuticals Biography: Vasant Jadhav is a Senior Vice President of Research at Alnylam Pharmaceuticals, where he ...
2022 Award for Science Outreach Winner Angela Messmer-Blust, PhD
Angela Messmer-Blust, PhD Associate Professor, RTI, UMass Chan Medical School Biography: Dr. Angela Messmer-Blust studied cell motility during her graduate studies at the University of Toledo where she received her Ph.D. (2009). She began her postdoctoral research at the CardioVascular Institute at Beth Israel ...
2022 Award for Patient Advocacy Winner Daniel O’Reilly, PhD
Daniel O’Reilly, PhD RTI, UMass Chan Medical School Biography: Daniel O’Reilly is currently a Post-Doctoral Associate in the Lab of Professor Anastasia Khvorova in the RNA Therapeutics Institute at the University of Massachusetts Chan Medical School. Dan earned his Ph.D. in Chemistry under the ...
